EXPERIENCE

Experience

OIRRC has provided reading center services to multiple Clinical Trials including but not limited to:

  • ACTH as A Re-emerging theRapy for Uveitis (ACTHAR) NCT02931175
  • A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema (DME) – VIDI Study NCT02302079
  • A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination with Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema – The iDEAL Study NCT01565148
  • Sirolimus as Therapeutic Approach to Uveitis – SAVE Study NCT00908466
  • Intravitreal Sirolimus as Therapeutic Approach to Uveitis – SAVE-2 NCT01280669
  • The READ-2 Study: Ranibizumab for Edema of the mAcula in Diabetes NCT00407381
  • Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose – the READ 3 Study NCT01077401
  • APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis NCT01960348
  • Study of DS-7080a for the Treatment of Neovascular Age-Related Macular Degeneration NCT02530918
  • A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI) NCT02247531
  • A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA) NCT02247479
  • Study to Evaluate Effects of Emixustat Hydrochloride in Subjects with Proliferative Diabetic Retinopathy NCT02753400
  • Study of the Safety, Tolerability, and Bioactivity of Tocilizumab on Patients with Non-infectious UVEITIS: The STOP-UVEITIS Study NCT01717170

Our Expertise